Tags

Type your tag names separated by a space and hit enter

Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis.
Prog Retin Eye Res. 2020 May 16 [Online ahead of print]PR

Abstract

Uveitis is a group of diseases characterized by intraocular inflammation, of which some are driven by autoinflammatory or autoimmune responses, such as Vogt-Koyanagi-Harada disease, Behçet's disease, uveitis associated with spondyloarthritis, ocular sarcoidosis, sympathetic ophthalmia and birdshot chorioretinopathy. These entities have various clinical forms, but genetic and biomarker data suggest that they share a common molecular basis, activation of the Interleukin (IL)-23/IL-17 pathway. Multiple factors including genetic predisposition, various cytokine imbalances, infectious agents and gut alterations are found to trigger an aberrant response of this pathway. The enhanced activity of the IL-23/IL-17 pathway is committed to the expansion and pathogenicity of Th17 cells. Evidence from animal models demonstrates that the development of pathogenic Th17 cells is responsible for the induction of experimental autoimmune uveitis. Further findings indicate that retinal pigment epithelium (RPE) cells may be a target of IL-17. IL-17 triggers downstream inflammatory cascades and causes dysfunction of RPE cells, which may affect retinal barrier function and thereby promote intraocular inflammation. Currently, several emerging drugs blocking the IL-23/IL-17 pathway have been assessed for the treatment of uveitis in pilot studies. The purpose of this is to summarize updated biological knowledge and preliminary clinical data, providing the rationale for further development and evaluation of novel drugs targeting the IL-23/IL-17 pathway in autoinflammatory and autoimmune uveitis. Future studies may focus on translational medicine targeting the IL-23/IL-17 pathway for the improvement of diagnosis and treatment of uveitis. In conclusion, activation of the IL-23/IL-17 pathway is a critical biological event and can be an important target for the treatment of autoinflammatory and autoimmune uveitis.

Authors+Show Affiliations

The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology and Chongqing Eye Institute, Chongqing, China.The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology and Chongqing Eye Institute, Chongqing, China.University Eye Clinic Maastricht, Maastricht, the Netherlands.The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology and Chongqing Eye Institute, Chongqing, China. Electronic address: peizengycmu@126.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32422390

Citation

Zhong, Zhenyu, et al. "Activation of the Interleukin-23/interleukin-17 Signalling Pathway in Autoinflammatory and Autoimmune Uveitis." Progress in Retinal and Eye Research, 2020, p. 100866.
Zhong Z, Su G, Kijlstra A, et al. Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis. Prog Retin Eye Res. 2020.
Zhong, Z., Su, G., Kijlstra, A., & Yang, P. (2020). Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis. Progress in Retinal and Eye Research, 100866. https://doi.org/10.1016/j.preteyeres.2020.100866
Zhong Z, et al. Activation of the Interleukin-23/interleukin-17 Signalling Pathway in Autoinflammatory and Autoimmune Uveitis. Prog Retin Eye Res. 2020 May 16;100866. PubMed PMID: 32422390.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis. AU - Zhong,Zhenyu, AU - Su,Guannan, AU - Kijlstra,Aize, AU - Yang,Peizeng, Y1 - 2020/05/16/ PY - 2020/03/18/received PY - 2020/04/30/revised PY - 2020/05/04/accepted PY - 2020/5/19/pubmed PY - 2020/5/19/medline PY - 2020/5/19/entrez KW - Autoimmunity KW - Autoinflammation KW - Interleukin-17 KW - Interleukin-23 KW - Th17 cells KW - Uveitis SP - 100866 EP - 100866 JF - Progress in retinal and eye research JO - Prog Retin Eye Res N2 - Uveitis is a group of diseases characterized by intraocular inflammation, of which some are driven by autoinflammatory or autoimmune responses, such as Vogt-Koyanagi-Harada disease, Behçet's disease, uveitis associated with spondyloarthritis, ocular sarcoidosis, sympathetic ophthalmia and birdshot chorioretinopathy. These entities have various clinical forms, but genetic and biomarker data suggest that they share a common molecular basis, activation of the Interleukin (IL)-23/IL-17 pathway. Multiple factors including genetic predisposition, various cytokine imbalances, infectious agents and gut alterations are found to trigger an aberrant response of this pathway. The enhanced activity of the IL-23/IL-17 pathway is committed to the expansion and pathogenicity of Th17 cells. Evidence from animal models demonstrates that the development of pathogenic Th17 cells is responsible for the induction of experimental autoimmune uveitis. Further findings indicate that retinal pigment epithelium (RPE) cells may be a target of IL-17. IL-17 triggers downstream inflammatory cascades and causes dysfunction of RPE cells, which may affect retinal barrier function and thereby promote intraocular inflammation. Currently, several emerging drugs blocking the IL-23/IL-17 pathway have been assessed for the treatment of uveitis in pilot studies. The purpose of this is to summarize updated biological knowledge and preliminary clinical data, providing the rationale for further development and evaluation of novel drugs targeting the IL-23/IL-17 pathway in autoinflammatory and autoimmune uveitis. Future studies may focus on translational medicine targeting the IL-23/IL-17 pathway for the improvement of diagnosis and treatment of uveitis. In conclusion, activation of the IL-23/IL-17 pathway is a critical biological event and can be an important target for the treatment of autoinflammatory and autoimmune uveitis. SN - 1873-1635 UR - https://www.unboundmedicine.com/medline/citation/32422390/Activation_of_the_interleukin-23/interleukin-17_signalling_pathway_in_autoinflammatory_and_autoimmune_uveitis L2 - https://linkinghub.elsevier.com/retrieve/pii/S1350-9462(20)30038-0 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.